Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Item

http://www.wikidata.org/entity/Q34626628

Q34626628

about

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management Advances in the management of myelofibrosis Emerging patterns of somatic mutations in cancer Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients Etiology and clinical relevance of elevated platelet count in ICU patients : A retrospective analysis.Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?JAK and MPL mutations in myeloid malignancies.Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Non-ST-segment elevation myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor: a case report.Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Tamoxifen-associated Budd-Chiari syndrome complicated by heparin-induced thrombocytopenia and thrombosis: a case report and literature review A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.Ruxolitinib for myelofibrosis--an update of its clinical effects.The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia.Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification.2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and T Class prediction models of thrombocytosis using genetic biomarkers.Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera.Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction.Evidence for organ-specific stem cell microenvironments Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera.Clinical and hematological presentation of children and adolescents with polycythemia vera.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.

P2860

Q24675681-430A4A12-0DED-4565-BCAA-751937F3424A Q26752940-50E58228-77E5-4B41-ACD7-374C95319F91 Q26772881-C5C67BA6-A05C-4BF2-AF30-2B679E62BC7F Q26795666-77D04BBC-55D1-420B-A551-B7C1DD493088 Q26851894-B6820619-8504-4DC0-8C98-8C0697E2B34C Q27008072-33C1750A-6545-4F44-82B1-46391B6B4DF9 Q27014126-F082C259-9316-47AE-B729-88972D57DD63 Q27687464-489FEE67-8D43-4AF0-B42B-F5AE1C81D07B Q28271752-CE403AD2-F50F-4FBB-932E-942C08D71F24 Q28307195-CF36F69F-1736-4920-AFB3-BBD0F0DBCD19 Q28533511-ABE97FDC-DDD2-48BE-BB65-C12FFF3B6E20 Q30313293-E375F285-54A8-4B89-ACC4-B30C1564AAC7 Q33359341-4A4EDC80-A755-47C9-B9BF-285C1E55D227 Q33378737-D5057C52-1B14-465B-9CA7-C2CBD7004EF1 Q33387514-92B98F47-136A-4937-8DB8-16EF210E945A Q33391506-2621C7DD-EE6B-4974-BCFB-B5B8CF7FBF25 Q33401757-EB7209BB-7533-44D2-8E9B-7F7B039F2DAD Q33402522-FD8F6247-30DF-4106-A1F1-D979717F9C32 Q33404691-8F5B0EA2-165D-4800-8137-59080E668088 Q33405372-916F86EA-9484-4E2E-BEB4-5F44B2E30F27 Q33406238-91D31CC0-8226-4199-B458-98D6F4E2E42F Q33406694-B0A4553E-80CF-4771-B913-A8A3493553D0 Q33411502-59C9E652-E826-411E-AB18-0F3E05E15A57 Q33418988-1988EE9E-8D0B-4571-BB08-9B623424A67E Q33423956-CA7D5DEA-DB27-45E9-AA8B-884CE3697A46 Q33435398-531F92AD-DE91-4099-938D-9C26F3EBE900 Q33509139-46812C7B-3432-450C-BBD0-9C738A44A322 Q33560755-5C02B789-5BDA-437F-B6D2-CBA6DD87B8EA Q33572605-7546D28B-EA33-4FBD-833C-D2C1FB65D1C4 Q33579530-4973350A-1001-4B60-9239-34DC8B57B676 Q33582246-4B85D4E4-E9D7-44CF-B6D0-87FB913ECC50 Q33717001-05A6C6C4-9DAB-442E-9DFB-996EFC151594 Q33753094-6AC810C6-F7A4-4622-A3CE-ACEB14B057B9 Q33788714-EC224AC3-8D46-4AAD-AEBD-6198D25D110F Q33870784-380E2071-9CE9-4407-8BFD-9A3D7D13602A Q33915577-0BD41052-3596-4A59-BFE4-22500BDB3DEB Q33982315-0FBE01D2-7FD2-4871-8676-1804716E73AA Q33995280-2BFFEB58-0079-446A-9A8F-1A265D8DCBF7 Q34054259-C68FA236-1FC2-48C5-90A3-5E89D960B381 Q34166859-4F1857BE-A4F3-4ED8-AB48-552ABAA2614E

P2860

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Item

http://www.wikidata.org/entity/Q34626628

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu